NOVN($15), for those not in it
This small cap pharma has a monopoly on the treatment of a contagious childrens skin disease with their new drug(ointment). I suspect they get FDA approval next year, and that at least 5M of the 6M people with this skin disease in the US will try the ointment, as it's 90%-100% effective at curing the disease on 43% of the patients in phase 3 just announced. If we assume that there are 5M+ new cases every year, then the potential remains high in the US alone. If the company simply makes $50/tube, then that would be $250M in revenues. However it will likely take more than one tube to cure the disease, as it's a 12 week course. Either way, with only 15M shares fully diluted, this one looks to be highly promising for stock appreciation at $15 or less. Target prices are now averaging around $30+
